Cancer research

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Retrieved on: 
Mittwoch, Mai 22, 2024
Patient, Disease, Radiation, Phase, TNT, Rectum, ANL, CCR, University, Trial of the century, Cancer, Trust, Chemoradiotherapy, Cancer research, Standard of care, ARTEMIS, Pharmaceutical industry

This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT’) (“CRT”) for the treatment of rectal cancer.

Key Points: 
  • This clinical study evaluates palupiprant (AN0025), a small molecule prostaglandin E receptor 4 (“EP4”) antagonist, with chemoradiotherapy and radiotherapy (total neoadjuvant therapy: ‘TNT’) (“CRT”) for the treatment of rectal cancer.
  • “This study aims to contribute to a transformation currently taking place in rectal cancer treatment.
  • For locally advanced rectal cancer, traditionally chemoradiation followed by radical surgery has been the standard of care, despite the significant morbidity associated with surgery.
  • Following the promising published phase 1b data, the current study assesses whether AN0025 increases the likelihood of achieving a cCR, when added to TNT in the treatment of locally advanced rectal cancer.

Enhanc3D Genomics Appoints Hazel Jones as Chief Executive Officer

Retrieved on: 
Mittwoch, Mai 15, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, 3D, Genomics, Patient, Doctor of Philosophy, University, Diagnosis, Drug development, Genome, Biomarker, Gene, Bachelor of Science, Cancer research, Combination, AstraZeneca, Management

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO.
  • Prior to joining Enhanc3D Genomics as COO in November 20231, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D.
  • Dr Chris Torrance, Chairman of the Board of Directors, Enhanc3D Genomics, said: “We're thrilled to officially appoint Hazel as CEO.
  • On behalf of the Board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the Company.”
    Dr Hazel Jones, Chief Executive Officer, Enhanc3D Genomics, added: “My time as COO and interim CEO has been highly rewarding, and I am now honoured and excited to have been appointed to continue to lead Enhanced Genomics as CEO.

Strengthening CAR-T Therapy to Work Against Solid Tumors

Retrieved on: 
Mittwoch, Mai 8, 2024
Immunotherapy, Brain, University, Blood, Prostate, Protein, Mouse, Pancreas, Ovary, Safety, Public health, See, Cancer research, Glioblastoma, Genetic engineering, Invention, TMIGD2, Canadian Aviation Regulations, Urology, National Cancer Institute, Research, Leukemia, Chimera, Lymphoma, CD276, Liver, Microbiology, Medicine, Bone marrow, Neoplasm, Lung, Paper, Antigen, Zang, Immune system, Albert Einstein, Vaccine

"CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.

Key Points: 
  • "CAR-T cell therapy has revolutionized the treatment of blood cancers such as leukemia and lymphoma but hasn't worked well against solid tumors," said Xingxing Zang, Ph.D. , the paper's senior author.
  • "We found that our changes to standard CAR-T cell therapy can significantly boost its effectiveness against solid tumors, including often-fatal pancreatic cancer and glioblastomas."
  • Dr. Zang and his colleagues created five CAR-T therapies that they tested on mice implanted with several types of solid human tumors.
  • He later realized that incorporating TMIGD2 into CAR-T cells might enable them to overcome the challenges posed by solid tumors.

Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded

Retrieved on: 
Montag, April 22, 2024
Science (journal), Mortality, FDA, Pediatric Research, Protein, Chromatin, Cell, Limb–girdle muscular dystrophy, Research, American Philosophical Society, National Cancer Institute, Molecular biology, Life, Gene, Quran, Food, LGMD, SMA, RNA, DMD, Spinal muscular atrophy, Infant, Dystrophin, Nationwide, Duchenne muscular dystrophy, Ageing, National academy, Hospital, Cancer research, Literature, DNA, Therapy, Gene expression, Muscular dystrophy, Chromosome, USD, Stanford University, Cancer, Islamic studies, Muscle weakness, Disease, Vilcek Foundation, Patient, Assay, Society, Listeria monocytogenes non-coding RNA, Pharmaceutical industry

Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.

Key Points: 
  • Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.
  • Gene therapy offers a solution by addressing this genetic anomaly, allowing the body to produce dystrophin and halt muscle degeneration.
  • Ludwig Professor of Cancer Research at Stanford University, has been awarded King Faisal Prize for Science in Biology.
  • Since 1979, King Faisal Prize in its 5 different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes.

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024

Retrieved on: 
Mittwoch, April 10, 2024
PSMA, Institute of Cancer Research, Cancer, MSLN, Clinical Cancer Research, Cancer research, Research, The Institute, Half-life, PD-L1, Prostate cancer, CD137, VH, Therapy, Patient, APC, Toxicity, AACR, Antibody, Annual general meeting, Dynamics (music), Pharmacology, NK

Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.

Key Points: 
  • Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer.
  • The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients.
  • “The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial.
  • The details of this research have also been published in Clinical Cancer Research, a journal of the AACR.

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

Retrieved on: 
Montag, April 8, 2024
Failure, Toxicity, Disease, Patient, Nebraska Medicine, University, Cancer research, PRS, Freezing, AACR, Neoplasm, Metastasis, Immune system, ASCO, Medical research, CRS, Pharmaceutical industry

FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.        

Key Points: 
  • FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
  • The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies.
  • The trial is ongoing, with results expected in the second half of 2024.

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
Montag, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Montag, März 25, 2024
Toxicity, B cell, CD8, Research, Cancer research, AACR, Chemokine, Therapy, Cytokine, Immune system, Poster, Viral, Decoy, Bacteria, Vaccine

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, will present a poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday morning, April 10th. An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research. The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.

Key Points: 
  • An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research.
  • The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.
  • The activity was associated with induction of human tumor cell killing by Decoy bacteria in the presence of immune cells.
  • Potentially unacceptable toxicity from this breadth of immune activation is avoided by using systemically administered killed bacteria as a delivery vehicle.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Dienstag, März 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research

Retrieved on: 
Mittwoch, März 20, 2024
Research, Liver disease, Discovery Science, Growth, Hematology, Patient, Cancer research, AACR, Publication, MSS, Therapy, Translational medicine, PD-L1, ICIS, Hepatotoxicity, Vaccine

Cancer Research, a journal of the American Association for Cancer Research (AACR), publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community.

Key Points: 
  • Cancer Research, a journal of the American Association for Cancer Research (AACR), publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community.
  • In the Cancer Research paper, we present studies used to characterize the differentiated preclinical features and mechanism of action of ATG-101, a tetravalent PD-L1/4-1BB bispecific antibody.
  • "The dedication and relentless efforts of our research team have led to the publication of the preclinical work in the prestigious journal Cancer Research and the development of a new clinical program," said Dr. Jay Mei, Antengene's Founder, Chairman and CEO."
  • [1] ATG-101 is a tetravalent PD-L1×4-1BB bispecific antibody that stimulates anti-tumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation.